Keep pulling the thread on Y Combinator.
Billion to One anticipates launching its ultra-sensitive minimal residual disease (MRD) test for stage 1 and 2 cancer patients in less than a year.
Billion to One believes its technology could eventually be used for early-stage cancer detection before a tumor reaches stage one, an achievement they consider the "holy grail" of the field.
Billion to One went public in late 2023 at a valuation exceeding $4 billion.
Billion to One claims to have nearly 20% market share in its target market.
Billion to One commercially launched an early version of its liquid biopsy cancer test in 2023.
In a case study, Billion to One's North Star Select liquid biopsy test identified microsatellite instability in a metastatic colorectal cancer patient, a finding missed by a traditional tissue biopsy, which made the patient eligible for immunotherapy.
Billion to One is operating as a profitable company.
One in 11 babies born in America this year will be screened by a genetic test that was not available a decade ago.
The prenatal test from Billion to One is one of the most widely used genetic tests in its market.
Billion to One processes more than 600,000 genetic tests per year.
Billion to One's core technology involves adding synthetic DNA molecules to a patient's sample before amplification to computationally measure and remove noise from the sequencing data.
Billion to One developed and launched its first commercial test within two years of its founding.